Safety and feasibility of third-party cytotoxic T lymphocytes for high-risk patients with COVID-19.
Grosso D, Wagner JL, O'Connor A, Keck K, Huang Y, Wang ZX, Mehler H, Leiby B, Flomenberg P, Gergis U, Nikbakht N, Morris M, Karp J, Peedin A, Flomenberg N.
Grosso D, et al. Among authors: wagner jl.
Blood Adv. 2024 Aug 13;8(15):4113-4124. doi: 10.1182/bloodadvances.2024013344.
Blood Adv. 2024.
PMID: 38885482
Free PMC article.
Clinical Trial.